Cadonilimab in Locally Advanced MSI-H/dMMR Colorectal Cancer
Status:
Recruiting
Trial end date:
2026-03-30
Target enrollment:
Participant gender:
Summary
This is a two-arm phase II clinical study to evaluate the efficacy and safety of Cadonilimab
(a PD-1/CTLA-4 bispecific antibody) in MSI-H/dMMR locally advanced colorectal cancer as the
regimen of neoadjuvant treatment. Eligible patients will receive Cadonilimab monotherapy for
eight cycles before surgery and part of patients may exempt from surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences